

REMARKS

Claims 1-19 are pending. Claims 18-19 are canceled herein, without prejudice.


In response to the restriction requirement, applicant hereby provisionally elects "Test Compound 1", N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid, found at page 103, lines 18-21 of the specification, with traverse. Applicant hereby submits that claims 1-5 and 8-17 are readable on the elected species. Applicants believe that there is unity of invention and all claims should be examined in the present application.

Applicants make the present election solely to comply with Office requirements for examination. It should not be construed as a disclaimer or surrender of any subject matter in the application. The right to file one or more divisional applications on the non-elected claims is reserved. It is expected that prior to issuance of a Notice of Allowance, that the Office will conduct a comprehensive search of the prior art that is commensurate with the scope of all pending claims.

Although it is not believed that any fees are needed to consider this submission, the Examiner is hereby authorized to charge our deposit account no. 04-1105 should any fee be deemed necessary.

Dated: June 20, 2007

Respectfully submitted,



Lisa Swiszczy Hazzard (Reg. No. 44,368)
EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874
Boston, Massachusetts 02205
Tel. No. (617) 517-5512